Results 11 to 20 of about 1,147,332 (293)

Current Status of Angiogenesis Inhibitors as Second-Line Treatment for Unresectable Colorectal Cancer. [PDF]

Cancers (Basel), 2023
Colorectal cancer is the third most common disease and the second most common cause of death around the world. The drug for second-line treatment depends on the drugs used in first-line treatment and the biomarker status.
Otsu S, Hironaka S.
europepmc   +2 more sources

Research Advances of PD-1/PD-L1 Inhibitors Combined with Angiogenesis Inhibitors in Treatment of Advanced Triple-negative Breast Cancer

Zhongliu Fangzhi Yanjiu, 2021
Advanced triple-negative breast cancer(TNBC) has less treatments, shorter survival time and poorer prognosis than other subtypes of breast cancer. The rapid development of immunotherapy in recent years is expected to prolong the survival time of advanced
HUANG Shifen, LING Xiaoling
doaj   +1 more source

An intuitionistic approach for the predictability of anti-angiogenic inhibitors in cancer diagnosis

Scientific Reports, 2023
Malignant cancer angiogenesis has historically attracted enormous scientific attention. Although angiogenesis is requisite for a child’s development and conducive to tissue homeostasis, it is deleterious when cancer lurks.
Syed Anas Ansar, Shruti Aggarwal, Swati Arya, Mohd. Anul Haq, Vikas Mittal, Fikreselam Gared   +5 more
doaj   +1 more source

Thalidomide is an inhibitor of angiogenesis. [PDF]

Proceedings of the National Academy of Sciences, 1994
Thalidomide is a potent teratogen causing dysmelia (stunted limb growth) in humans. We have demonstrated that orally administered thalidomide is an inhibitor of angiogenesis induced by basic fibroblast growth factor in a rabbit cornea micropocket assay.
R J, D'Amato, M S, Loughnan, E, Flynn, J, Folkman   +3 more
openaire   +2 more sources

Questionnaire survey of angiogenesis inhibitor-related oral complications based on a nation-wide study in Japan

Journal of Dental Sciences, 2021
Background/purpose: The prevalence of oral adverse events and dental treatments related complications during the molecular targeted drugs therapy remains unclear.
Shin-ichi Yamada, Hiroshi Kurita, Akira Tanaka, Masaru Miyata, Yoshinari Morimoto, Akira Yamaguchi, Souichi Yanamoto, Hiromasa Yoshikawa, Yutaka Imai   +8 more
doaj   +1 more source

Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma

IJU Case Reports, 2020
Introduction Nivolumab is effective for advanced renal cell carcinoma; however, reports are limited wherein nivolumab is combined with sequential therapy of angiogenesis inhibitors and metastasectomy.
Hiroki Hagimoto, Soki Kashima, Kazuki Doi, Shintaro Nakayama, Takanori Sano, Satoshi Imai, Tomihiko Yasufuku, Mototsugu Muramaki, Yuji Yamada   +8 more
doaj   +1 more source

The Vasohibin Family

Pharmaceuticals, 2010
Angiogenesis is regulated by the local balance between angiogenesis stimulators and inhibitors. A number of endogenous angiogenesis inhibitors have been found in the body. The origin of these inhibitors is mostly extrinsic to the vasculature.
Yasufumi Sato
doaj   +1 more source

Angiogenesis Inhibitors from Natural Sources [PDF]

, 2016
A multi-target strategies targeting on various biochemical and physiological pathways implicated in tumour pathogenesis should be developed with the ultimate aim to manage patients with cancer and reduce the normal-tissue toxicity. Tumor angiogenesis has
Awang Hamsin, Dayang Erna Zulaikha, Abd Hamid, Roslida, Roslida Abd Hamid, Dayang Erna Zulaikha Awang Hamsin   +3 more
core   +1 more source

Study of endostatin, tumstatin and PEDF, the natural angiogenesis inhibitors, potential in avasculargenic therapy

Oftalʹmologiâ, 2014
Purpose: To evaluate the potential of endostatin, tumstatin and PEDF in avasculargenic therapy.Methods: The avasculargenic potential of the natural angiogenesis inhibitors was explored on the model of alkaline burn, attended with angiogenesis of cornea ...
V. G. Likhvantseva, E. V. Arutyunyan, A. I. Miroshnikov, A. Yu. Salihov, O. V. Belous, K. D. Kurtshalidze, R. S. Esipov, K. A. Bejrahova,, V. N. Stepanenko   +8 more
doaj   +3 more sources

Current clinical application progress in angiogenesis inhibitors

上海师范大学学报. 自然科学版, 2018
Inhibition of angiogenesis is an established modality of cancer treatment.We summarized angiogenesis inhibitors of three modalities:single-target,multi-target and broad-spectrum agents.We discussed the clinical efficacy of monoclonal antibodies,small ...
Lu Yu
doaj   +1 more source